Introduction
T he clinical success of osteochondral tissue engineering relies upon the generation of a functional tissue of physiologically relevant size that is capable of integration at the repair site. Bone has an extensive blood supply that is critical to the tissue's viability and function. In the clinic, disruption or lack of blood supply to bone causes osteonecrosis and is implicated in the pathogenesis of nonunion fractures. 1 Conversely, the presence of blood vessels in articular cartilage is associated with various pathologies, including osteoarthritis 2, 3 rheumatoid arthritis, 4 and inferior repair tissue in autologous chondrocyte implantation. 5 One approach to osteochondral tissue engineering is to create a biphasic construct in vitro whereby constituent cells have reached a suitable level of chondrogenic and osteogenic differentiation before implantation. 6 However, nutritional limitations posed by diffusion gradients currently limit the size of viable tissues that can be engineered. [7] [8] [9] Moreover, the viability and successful integration of such constructs into osteochondral defects relies upon vascular ingrowth after in vivo implantation. Therefore, much attention is now focused on tissue engineering vascularised constructs. Current strategies include incorporating vascular cell types, 10, 11 or the addition of slow release angiogenic growth factors bound to scaffolds. 12, 13 Vascularised bone constructs have also been engineered in vivo by endocultivation, whereby a construct is implanted intramuscularly to allow vascular ingrowth before reimplantation into the defect site.
BMSCs has been used to repair long bone 15, 16 and cartilage defects. [17] [18] [19] However, it is not clear if, or how, in vitro differentiated BMSCs may affect vascular ingrowth once reimplanted into osteochondral defects. Undifferentiated BMSCs elicit potent angiogenic effects which appear to be due to a combination of direct cellular interactions and by the release of soluble factors. In vitro, BMSCs secrete AU3 c VEGF, FGF-2, interleukin-6, AU4 c PIGF, angiopoeitin-1, AU3 c PDGF, plasminogen activator, AU3 c MMP-9 and monocyte chemotactic protein-1 (MCP-1). 20, 21 BMSC conditioned media stimulates endothelial cell proliferation and migration 20 and tube-like formation. 21 Neutralising antibody experiments have demonstrated that the mitogenic effects of BMSC secretome were not solely due to the presence of one particular growth factor, but a combination of factors. 20 In vivo, improved vascular ingrowth and osteogenesis at the fracture site was observed after implantation of gelatin sponges containing MSC conditioned media in rats. 22 Similarly, injection of BMSC conditioned media improved blood flow in a mouse model of hindlimb ischaemia. 20 BMSCs have also been reported to stimulate vascularisation in animal models of myocardial infarction. 23, 24 Conversely, there is also evidence to suggest that BMSCs may inhibit angiogenesis. Otsu et al. reported that direct cell-cell contact between rat BMSCs and endothelial cells caused apoptosis and destruction of endothelial tube-like structures on MatrigelÔ. Furthermore, in their mouse melanoma model, BMSCs appeared to abrogate tumour growth by inhibiting tumour angiogenesis. 25 It is currently unknown whether these predominantly proangiogenic properties of undifferentiated BMSCs are conserved after in vitro chondrogenic or osteogenic differentiation and the accompanying change from a 2D to 3D environment. In the present study, equine BMSCs (eBMSCs) were differentiated along chondrogenic and osteogenic lineages in 3D pellet culture as previously described. 26 Angiogenic properties of undifferentiated and differentiated cells were analyzed by collecting serum-free conditioned media and (1) screening it for angiogenesis-related proteins and (2) applying it to an in vitro angiogenesis assay, which measures the degree of endothelial tube-like formation on Matrigel. Our results show that conditioned media from undifferentiated eBMSCs supports endothelial tube-like formation in vitro and contains an array of angiogenic, antiangiogenic and neurotrophic factors. We present novel data showing that when differentiated along chondrogenic and osteogenic lineages, eBMSCs reduce production of angiogenesis and neurogenesis-related proteins and produce a soluble factor(s) that inhibits endothelial tube-like formation in vitro.
Materials and Methods
Cell culture eBMSCs were isolated from the bone marrow of the third metacarpal of distal forelimbs from four horses (mean age 7 years) as previously described. 26 Four days after isolation, flasks were washed to ensure removal of haematopoietic cells. eBMSCs were incubated at 37°C at 5% CO 2 and received media changes with eBMSC medium (DMEM + GlutaMAX , 100 mg mL -1 gentamicin, 10% foetal calf serum [FCS] [PAA]) three times a week. At each passage, population doublings were calculated using the following formula: LOG10 (final cell number/initial cell number))*3.33.
Subsequent differentiation assays and generation of conditioned media were performed using eBMSCs that had undergone approximately 25 population doublings (p2-3).
Monolayer adipogenic and osteogenic differentiation eBMSCs were seeded into six-well plates at 3 · 10 3 cells/ cm 2 Chondrogenic and osteogenic differentiation in 3D pellet culture eBMSCs were chondrogenically and osteogenically differentiated in defined media using a previously described pellet culture system. 26 To make cell pellets, eBMSCs, suspended in either chondrogenic or osteogenic differentiation media, were transferred into 1.5 mL Eppendorf tubes (0.5 · 10 6 cells per Eppendorf) and centrifuged at 500 g for 5 min. Chondrogenic differentiation medium consisted of: DMEM + GlutaMAX TM-1 , 2% FCS, 100 mg mL -1 gentamicin, 10 mg mL -1 Insulin-Transferrin-Selenium-X (Gibco), 0.1 mM L-ascorbic-acid-2-phosphate, 10 nM dexamethasone and 10 ng mL -1 TGF-b1 (Peprotech). Osteogenic differentiation medium was as described for monolayer differentiation. Pellets were incubated at 37°C and 5% CO 2 for 21 days with media changes three times a week.
Generation of conditioned media
Serum-free conditioned media was generated from undifferentiated cells, chondrogenic and osteogenic pellet cultures of eBMSCs. 27 Undifferentiated eBMSCs were cultured until 70% confluent, washed twice with phosphate-buffered saline (PBS) and incubated with 20 mL of conditioning media (serum free DMEM + GlutaMAX TM-1 , 100 mg mL -1 gentamicin supplemented with 10 mg mL -1 Insulin-TransferrinSelenium-X and 1% MEM nonessential amino acids [Gibco]) per T75 flask. Conditioning media was incubated with cells for 4 days, filtered through a 0.45 mm filter (Sarstedt) and stored at -20°C. Upon collection of conditioned media, cells were passaged and a cell count performed. For chondrogenic/osteogenic pellets, at day 21, pellets were washed twice in PBS and incubated with 1 mL of conditioning media per pellet. Conditioned media was collected after 4 days and processed as described above. Pellets were snap frozen in liquid nitrogen cooled hexane and stored at -80°C.
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Histological and immunohistochemical analysis of pellet cultures
Histology and immunohistochemistry was performed on 7 mm cryosections from a minimum of four pellets per horse (16 chondrogenic & 16 osteogenic) . Toluidine blue was applied to cryosections for 1 min, washed and air dried overnight before being mounted in Pertex (Histolab Ò ). For Von Kossa staining, 5% silver nitrate (VWR) in distilled water was applied to cryosections and placed under a UV light until brown colour development (*2 min). Sections were washed with 2% sodium thiosulphate (BDH) in distilled water, dehydrated then mounted with Pertex.
Immunohistochemistry was carried out at room temperature unless otherwise stated. For type II collagen, cryosections were pretreated with 4800 U/mL ovine testicular hyaluronidase (Sigma) and 0.25 U/mL chondroitinase ABC (MP Biomedicals) in Tris acetate buffer pH 8 for 2 h. Sections were fixed in 10% formalin, blocked with 5% goat serum (Vector), then incubated with mouse anticollagen type II (CIIC1, DSHB) (1:10 in PBS) overnight at 4°C. Negative controls were incubated with mouse IgG1a (Dako). The secondary antibody goat anti-mouse Alex Fluor 488 (Invitrogen) (1:200 in PBS) was applied to sections for 1 h. After washing in PBS, sections were mounted with Vectashield mounting medium for fluorescence containing DAPI (Vector) and observed using a Leitz Diaplan light microscope. For type X collagen, cryosections were fixed in a solution of methanol and acetone for 10 min, washed in PBS, then treated with 1 mg/mL protease in PBS (Sigma; P-6911) for 30 min. Sections were blocked with 5% bovine serum albumin (BSA) in PBS for 30 min, then incubated with mouse anticollagen type X antibody (a kind gift from Gary J. Gibson, Henry Ford Hospital, Detroit, MI) (1:300 in PBS containing 1% BSA) overnight at 4°C. An isotype matched mouse immunoglobulin was used as a negative control. Sections were incubated with goat anti-mouse Alexa Fluor 594 (Invitrogen) (1:200 in PBS containing 1% BSA) for 45 min. Slides were washed in PBS then mounted with Vectashield mounting medium for fluorescence containing DAPI (Vector) and observed using Leica TCS SP2 AOBS confocal microscope.
DNA quantification assay
DNA content of undifferentiated, chondrogenically and osteogenically differentiated eBMSCs that generated a standard volume of conditioned media was calculated using the Quanti-iTÔ PicoGreen Ò assay (Invitrogen). Pellets/undifferentiated eBMSCs were digested in 1.25 mg/mL Proteinase K (Sigma) in 100 mM ammonium acetate (Sigma) containing 7% EDTA (BDH) in distilled water, at pH 7 at 60°C overnight. Briefly, 200 mL of pellet/cell digest were diluted in Tris-EDTA buffer and pipetted in triplicate into a 96-well plate. PicoGreen reagent was incubated with samples for 5 min at room temperature. Fluorescence was measured using a fluorescent microplate reader (FLx800 microplate fluorescence reader; Bio-Tek Instruments) at (excitation wavelength 480 nm, emission wavelength 520 nm).
Angiogenesis array
A sample of conditioned media from undifferentiated, chondrogenically, and osteogenically differentiated eBMSCs from each horse was screened for angiogenesis-related proteins using a Human Angiogenesis Proteome ProfilerÔ antibody array (R&D Systems) according to the manufacturer's instructions. Positive signals were detected by chemiluminescence (UptiLight US WBlot HRP chemiluminescent detection reagent; Interchim) and visualised with ChemiDOcÔ EQ (Bio-Rad). Array data was quantified by measuring the sum of the intensities of the pixels within the spot boundary · pixel area with image analysis software (Quantity One Ò version 4.6.3; Bio-Rad). Array data was normalized to background then DNA content as calculated for each culture from each respective horse.
Endothelial tube-like formation assay
Endothelial tube-like formation assays were performed using Matrigel (growth factor reduced, phenol red-free [BD Biosciences]). Twenty-four-well tissue culture plates were coated with 230 mL Matrigel per well and allowed to solidify at 37°C for 30 min. The human dermal microvascular cell line, HMEC-1, was seeded onto Matrigel (1 · 10 5 per well) in MCDB 131 medium, 0.05% penicillin and streptomycin (both Gibco) and 10% FCS. After 4 h plates were washed gently thrice before application of either undifferentiated, chondrogenically or osteogenically differentiated eBMSC conditioned media. Conditioning media that had not been in contact with cells was used for controls. Time lapse images were captured over a 24 h period using a video camera set up to an Olympus CK2 microscope. After 24 h, wells were washed and viewed in phase using a Nikon TS100 fluorescent microscope.
Total tube length in five fields of view per well was quantified by drawing over and measuring tube-like structures using image analysis software (IPLab version 3.6; Becton Dickinson) ( b F1 Fig. 1A) . Complexity of tube-like networks was scored using an adapted scoring system by Mcilroy et al. (Fig. 1B) . 28 Two cells sharing a common branching point were scored as 1 (''a'' in Fig. 1B) ; three cells sharing a common branching point were scored as 2 (''b'' in Fig. 1B ) and so on. Angiogenic sprouts, classified as an unconnected tube-like structure 25-100 mm in length were scored as 1. Data for total tube length and branching score were normalized to the DNA content calculated for each culture from each respective horse.
Mass spectrometry
Undifferentiated, chondrogenically, and osteogenically differentiated eBMSC conditioned media from three horses was analysed by LC-MS/MS mass spectrometry. Conditioned media was concentrated 10 · using Amicon Ultra-2 centrifugal filter devices (10 kDa molecular weight cut off) according to the manufacturer's instructions (Millipore), digested with trypsin at 37°C then separated by liquid chromatography. MS/MS analysis was performed on fractionated peptides using a 4800 MALDI TOF/TOF mass spectrometer (Applied Biosystems). The search engine ''MASCOT'' was used to identify peptides from the NCBI database. Peptides with a total ion score > 95% confidence interval or with a peptide count of > 2 were excluded. Unamed or hypothetical proteins were identified using an online bioinformatics database (DAVID).
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Statistical analysis
With the exception of growth kinetics, data from all horses were pooled before statistical analysis. Differences between treatment groups and controls were tested for statistical significance using Analyse-it Ò . All data presented a nonnormal distribution as determined using the Anderson Darling test for normality and Levene's test for equality of variances. Data from the three treatment groups were tested for significant differences using a Kruskal-Wallis one-way analysis of variance test. eBMSCs from all 4 horses demonstrated adipogenic and osteogenic differentiation in 2D differentiation assays. Adpiogenic differentation of eBMSCs was confirmed by the presence of intracellular lipid droplets as shown by oil red O staining (Fig. 2B, C) . Differentiated cells were larger and less bipolar in morphology compared to controls. Osteogenic differentiation of eBMSCs was indicated by the presence of alkaline phosphatase (Fig. 2D, E) . (Fig. 3B) . Osteogenic pellets contained little sulphated glycosaminoglycan (sGAG) (Fig.  3C) , whereas chondrogenic pellets demonstrated strong metachromatic staining with toluidine blue indicating a sGAG-rich matrix (Fig. 3D ). All osteogenic pellets displayed a mineralised matrix as shown by Von Kossa staining (Fig.  3E) . In contrast, none of the chondrogenic pellets stained positively with Von Kossa (Fig. 3F) . Immunohistochemistry demonstrated positive labelling of type II collagen in chondrogenic pellet cultures (Fig. 3G-H) . Type X collagen was detected in discrete regions of chondrogenic pellets (Fig. 3J) , as confirmed by an equine growth plate positive control (Fig. 3K) . Neither collagen type II or type X were found immunohistochemically in osteogenic pellets (not shown). Appropriately matched isotype controls for both type II and type X collagen antibodies were negative (Fig. 3I, L , respectively). b AU5 (Supplementary Data are available online at www.liebertpub.com/tea). Fewer tube-like networks formed when HMEC-1 were cultured for 24 h with either chondrogenic (Fig. 4A) or osteogenic (Fig. 4B) conditioned media compared to both controls (conditioned media from undifferentiated cells and control media that had not been in contact with cells). Total tube length (Fig. 4E ) and branching score (Fig. 4F) were significantly less when endothelial cells were cultured with chondrogenic or osteogenic conditioned media compared to controls (Fig. 4E , all comparisons: p < 0.0001, Kruskal-Wallis).
Results
Growth kinetics and mutipotency of eBMSCs
Chondrogenically and osteogenically differentiated eBMSCs reduced production of both angiogenic and antiangiogenic proteins Conditioned media from undifferentiated, chondrogenically and osteogenically differentiated eBMSCs was screened for the presence of angiogenic/antiangiogenic factors using an antibody array, which detects the relative levels of 55 different angiogenesis related proteins. Six angiogenic (DPPIV, MMP-9, endothelin-1, PDGF-AA, AU4 c UPA, and VEGF) and four antiangiogenic proteins (TIMP-1, IGFBP-2, PF4 and angiopoietin-2) were detected at higher levels compared to all other proteins ( F5 c Fig. 5A , E, respectively). Undifferentiated eBMSC conditioned media contained significantly higher levels of angiogenesis-related proteins compared to chondrogenic and osteogenic conditioned media, with the exception of DPPIV, VEGF, and PDGF-AA, which were not significantly different between undifferentiated and chondrogenic conditioned media (Fig. 5A-G) . Interestingly, chondrogenic conditioned media contained higher levels of angiogenic factors, PDGF-AA ( p = 0.0079), VEGF ( p = 0.0497), FGF-2 ( p = 0.0363), FGF-4 ( p = 0.0126), FGF-7 ( p = 0.0225), MCP-1 ( p = 0.0363) and activin A ( p = 0.0230), and the antiangiogenic factor, IGFBP-3 ( p = 0.0188), compared to osteogenic conditioned media.
Chondrogenically and osteogenically differentiated eBMSCs reduced production of neurotrophic proteins
Undifferentiated eBMSC conditioned media also contained higher levels of neurogenic factors compared to chondrogenic and osteogenic secretome (Fig. 5H) . Levels of artemin were significantly higher in undifferentiated compared to both chondrogenic ( p = 0.0209) and osteogenic ( p = 0.0079) conditioned media. Undifferentiated eBMSC secretome contained significantly more persephin than osteogenic conditoned media ( p = 0.0044). Both chondrogenic ( p = 0.0126) and osteogenic ( p = 0.0002) conditoned media contained less glial cell-derived neurotrophic factor (GDNF) compared to undifferentiated conditioned media, with chondrogenic conditioned media containing higher levels of the neurotrophin compared to osteogenic secretome ( p = 0.0363).
Proteomic analysis of eBMSC conditioned media
After applying a stringent set of exclusion criteria, almost all peptides detected in eBMSC conditioned media by mass spectrometry were identified as ECM proteins. Type I collagen peptides were identified in all samples ( T1 c Table 1 ). Chondrogenic conditioned media contained multiple fibronectin peptides. Fibronectin was also detected in the secretome of undifferentiated and osteogenically differentiated eBMSCs (two of the three BMSC populations tested). Peptides of cartilage-associated matrix proteins biglycan and decorin were identified in chondrogenic conditioned media. Similary, type II collagen and lumican were identified in two out of the three samples of chondrogenic secretome. The presence of these peptides are indicative of a cartilaginous ECM; thus, further confirming the chondrogenic phenotype of differentiated eBMSCs. Peptides of the antiangiogenic molecule thrombospondin were detected in two out of three samples of chondrogenic and in one sample of both undifferentiated and osteogenic conditioned media. Bone sialoprotein-2 was also present in the chondrogenic conditioned media from two out of the three BMSC populations tested and at 94.6% confidence interval in the third sample.
Discussion
In the present study, we show for the first time, that when either chondrogenically or osteogenically differentiated in a 3D culture system, eBMSCs reduce production of angiogenesis and neurogenesis-related proteins and inhibit angiogenesis in vitro. With respect to osteochondral tissue engineering, this supports the use of BMSCs for avascular cartilage formation; however, maybe of concern for the generation of vascularised bone.
Initially, eBMSCs proliferated rapidly in culture, which is concominant with other studies examining the growth kinetics of eBMSCs in vitro. 26, 29 We have previously shown that these cells express the putative stem cell markers CD90, CD166 and STRO-1. 26 eBMSCs demonstrated multipotency
FIG. 3. AU7 c
Haematoxylin and eosin staining of (A) osteogenic and (B) chondrogenic pellets. Metachromasia of (C) osteogenic and (D) chondrogenic pellets using toluidine blue indicates a sulphated glycosaminoglycan rich matrix in chondrogenic pellets. as shown by their ability to differentiate along adipogenic, osteogenic and chondrogenic lineages. In addition to standard differentiation in monolayer, osteogenic differentiation was performed in a 3D pellet culture system as previously described. 30 Mineralization of osteogenic pellets shown by Von Kossa and haematoxylin and eosin suggest that eBMSCs differentiated osteogenically. Previous 3D osteogenic differentiation of these cells has also identified the presence of osteocalcin immunohistochemically. 26 Chondrogenic differentiation was demonstrated by the presence of sGAG and type II collagen; however, discrete regions of type X collagen immunostaining indicate areas of hypertrophy. This, together with the identification of bone sialoprotein in chondrogenic conditioned media, suggest differentiation of eBMSCs toward a hypertrophic phenotype.
Hypertrophy of chondrogenically differentiated BMSCs in pellet culture is widely reported in the literature. 26, [31] [32] [33] [34] In endochondral ossification, hypertrophic chondrocytes are proangiogenic, producing VEGF, which leads to vascular invasion and ossification of the cartilage anlagen. 35 Although we observed a degree of hypertrophy, chondrogenic eBMSC secretome was antiangiogenic. Our findings highlight important differences between the phenotypes of nascent hypertrophic chondrocytes compared to MSC that have been manipulated to differentiate chondrogenically in vitro.
Conditioned media from undifferentiated eBMSCs supported the formation of endothelial tube-like structures, although this was comparable to controls. This suggests angiogenic factors detected in undifferentiated eBMSC conditioned media did not further enhance tube-like formation.
FIG. 4.
Matrigel assays 24 h after treatment with eBMSC conditioned media. Representative images showing endothelial tube-like formation after treatment with (A) chondrogenic, (B) osteogenic, (C) undifferentiated, and (D) control conditioned media. (E) Tube-like length and (F) branching score were significantly greater when endothelial cells were cultured with control media or undifferentiated eBMSC conditioned media compared to both chondrogenic and osteogenic conditioned media. Data shown are medians, error bars represent minimal and maximal data points (***p < 0.0001, Kruskal-Wallis, n = 12).
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FIG. 5. Angiogenic, antiangiogenic, and neurotrophic factors identified in eBMSC conditioned media, normalised to DNA content. Undifferentiated eBMSC secretome generally contained higher levels of angiogenic, antiangiogenic, and neurotrophic factors compared to both chondrogenic and osteogenic conditioned media. This is contrary to a study by Hung et al., who reported stimulation of endothelial tube formation by human BMSC secretome. 21 Hung et al. used a different cell line and method for the generation of conditioned media and performed the Matrigel assay under hypoxic conditions, which could account for such discrepancies. Our data show significant inhibition of endothelial tube-like formation when HMEC-1 were cultured with conditioned media from chondrogenically or osteogenically differentiated eBMSCs. eBMSCs produced lower levels of antiangiogenic factors following 
ANTIANGIOGENIC PROPERTIES OF DIFFERENTIATED MSCS 9
differentiation; therefore, this antiangiogenic activity cannot be accounted for by the presence of these inhibitory molecules. Therefore, we propose, that differentiated cells produced one or more soluble factor(s) not present on our protein-antibody arrays that inhibited endothelial cells by either an angiogenic specific or nonspecific mechanism. It is possible that antiangiogenic proteins previously reported in cartilaginous tissues, such as chondromodulin 36, 37 may have been responsible. Endothelial tube formation assays using Matrigel are highly sensitive, reproducible assays, used to model angiogenesis in vitro (reviewed by Staton et al.) . 38 We used growth factor-reduced Matrigel, to avoid any interference from endogenous factors. However, being composed of murine tumor eCM proteins, Matrigel does not precisely model the vascular microenvironment associated with osteochondral tissues. Species difference is also a noteworthy consideration of our study (equine-human). Whether the observed antiangiogenic effects of eBMSCs would be recapitulated by human BMSCs in vivo is unclear and requires further investigation.
With the aim of identifying this soluble antiangiogenic factor(s), conditioned media was analysed by mass spectrometry. The only known antiangiogenic peptide identified was thrombospondin in two samples of chondrogenic and in one sample of osteogenic and undifferentiated conditioned media, respectively. However, thrombospondin was detected by protein-antibody array at higher levels in undifferentiated compared to differentiated eBMSC secretome, making it unlikely to be responsible for the inhibition of endothelial tube-like formation. Mass spectrometry did not identify any other angiogenesis-related proteins, which is likely due to masking by more abundant ECM proteins, such as the collagens.
Angiogenic factors have been previously identified in undifferentiated BMSC conditioned media. 20, 21 The results presented here demonstrate, for the first time, reduction of angiogenesis-related proteins when BMSCs are differentiated in a 3D culture system toward chondrogenic and osteogenic lineages. This finding does not appear to have been reported previously in the literature with any species of BMSC. It could be argued that the change in culture environment rather than the differentiation status of the cells reduced secreted levels of angiogenesis-related proteins. However, this is not supported by a previous study, which reported an increase in production of angiogenic factors by BMSCs upon transition from a 2D to 3D culture system. 39 Moreover, our data reveal significant differences in levels of angiogenesisrelated proteins between chondrogenic and osteogenic cultures. Thus, it is clear that the state of cellular differentiation affects the angiogenesis-related protein secretome profile of eBMSCs. The effect of 2D versus 3D culture could be further investigated by culturing eBMSC pellets in standard media as a control. However, this is complicated by the fact that BMSCs may spontaneously differentiate chondrogenically in pellet culture in the absence of chondrogenic growth factors, such as TGF-b. 40, 41 Angiogenesis and osteogenesis are coupled in vivo, which is reflected by cross-talk between vascular and osteogenic cell types in vitro (reviewed by Grellier et al.) . 42 Osteoblasts produce VEGF, 43 an important angiogenic growth factor, which may also influence osteogenesis as it can function to recruit osteoprogenitor cells and stimulate their differentiation into osteoblasts. 44, 45 Recently, endothelial cells have been shown to promote osteogenic differentiation of BMSCs in a 3D spheroid coculture model. 46 Thus, cellular communication between bone/cartilage forming and vascular cells may not only influence the vascularisation of osteochondral tissues but may also affect repair tissue composition. Considering the above, we were surprised to observe antiangiogenic properties of osteogenically differentiated eBMSCs. However, our findings are supported by a recent study in which BMSC secretome reduced endothelial tube-like formation and angiogeneic factor production after osteogenic differentiation in monolayer. 47 Importantly, we and the aforementioned author examined the angiogenic properties of in vitro differentiated BMSCs at one stage of cellular differentiation. It is possible that the angiogenic properties of differentiating BMSCs change in a temporal manner as the cells become more committed.
Our findings have important implications for the development of vascularised osteochondral constructs, utilizing the regenerative capacity of BMSCs. Antiangiogenic paracrine activity of chondrogenically and osteogenically differentiated BMSCs may prevent subchondral vascular ingrowth upon in vivo transplantation into the defect site. This would reduce viability, function, and integration of the osseous portion of the construct and potentially compromise the nutritional supply to the overlying articular cartilage. There are several strategies that may negate this problem by promoting vascularisation: (1) refine/manipulate osteogenic differentiation of BMSCs to promote their angiogenic capacity (2) prevascularise the osseous portion of the construct by either incorporating vascular cells 10, 11 or by intramuscular endocultivation techniques 14, 48 or (3) angiogenic priming of the osseous portion of the construct by slow release angiogenic factor delivery systems. 12, 13, 49 Undifferentiated human BMSCs elicit neurogenic effects, which are attributed, in part, to production of neurotrophins. 27, [50] [51] [52] Here eBMSCs produced neurogenic proteins, GDNF, NRG1-b1, persephin and artemin, when chondrogenically/osteogenically differentiated. The fact that chondrogenic and osteogenic differentiation resulted in reduced angiogenic and neurogenic properties of eBMSCs is noteworthy, since during development angiogenesis and neurogenesis often occur simultaneously and are regulated by similar molecular mechanisms. 53, 54 For future work it would be interesting to investigate the effect of conditioned media from chondrogenically and osteogenically differentiated BMSCs on in vitro models of nerve growth and to examine potential interplay between soluble angiogenesis and neurogenesis-related factors.
In conclusion, when either chondrogenically or osteogenically differentiated, eBMSCs exert antiangiogenic effects by paracrine activity. With respect to in vitro osteochondral tissue engineering this would be beneficial for maintaining an avascular articular cartilage but undesirable for bone formation. Future work in this field is required to differentially regulate vascularisation in tissue engineered bone and cartilage to improve osteochondral tissue engineering therapies for clinical use.
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